Looking through RBG crumbs and decided to look into the who are the doctors drop. The Q drop was January 6 and there's an article on January 2, 2019 about memorial sloan kettering cozying up with big pharma. So only 4 days between the article and Q post.
Q !!mG7VJxZNCI ID: 38db44 No.4627556 📁
Jan 6 2019 12:32:35 (EST)
…
Who are the doctors 'currently' treating [RBG]?
What other political [former/current] sr. political heads are they affiliated w/?
What 'off-market' drugs are being provided to [RBG] in order to sustain minimum daily function?
What is the real medical diagnosis of [RBG]?
Who is managing her care?
Who is 'really' managing her care?
The clock is ticking.
PANIC IN DC.
Q
Some article snippetts
http://archive.fo/uZmsc
https://www.fiercehealthcare.com/hospitals-health-systems/memorial-sloan-kettering-s-season-turmoil
Hospitals & Health Systems
Memorial Sloan Kettering’s season of turmoil
by Katie Thomas, The New York Times, Charles Ornstein, ProPublica | Jan 2, 2019 12:05pm
One by one, they stood up to challenge the stewardship of their beloved institution, often to emotional applause. Some speakers accused their leaders of letting the quest to make more money undermine the hospital’s mission. Others bemoaned a rigid, hierarchical management that had left them feeling they had no real voice in the hospital’s direction.
“Slowly, I’ve seen more and more of the higher-up meetings happening with people who are dressed up in suits as opposed to white coats,” said Viviane Tabar, M.D., chairwoman of the neurosurgery department.
“The corporatization of this institution is clear to many of us who have been here a long time,” said Carol L. Brown, M.D., a gynecologic cancer surgeon, according to an audio recording of the meeting.
The turmoil followed reports by The New York Times and ProPublica that the hospital’s chief medical officer, José Baselga, M.D., Ph.D., had been paid millions by drug and healthcare companies and failed to disclose those ties more than 100 times in medical journals, and that hospital insiders had made lucrative side deals that stood to earn them handsome profits, sometimes for work they had done on the job.
Closer ties between nonprofit research centers like Memorial Sloan Kettering and corporations are being fueled by a rush of potentially breakthrough cancer treatments. Venture capital firms and drug companies have looked to cash in on the scientific discoveries, said Brad Loncar, the founder of an investment fund that focuses on cancer. “Money follows success,” he said, and Memorial Sloan Kettering has been a focus “because they conduct terrific science there.”
In recent years, the hospital, like its competitors, has struck increasingly sophisticated deals to commercialize its discoveries, in some cases receiving equity stakes in startups rather than simply collecting royalties.
The predicament of Memorial Sloan Kettering also reflects a shift in its own culture. Its prior chief executive, Harold E. Varmus, M.D., a Nobel Prize-winning scientist, personally kept companies at arm’s length, while Thompson, also a respected cancer researcher, has more fully embraced such relationships. The new approach has been applauded by some for expanding access to the cancer center’s discoveries, even as others have worried that the hospital may be losing sight of its mission.
Its leaders and top researchers also hold influential positions in the corporate world. When news of Baselga’s disclosure lapses broke in September, 12 doctors and researchers at the hospital served on the boards of publicly traded companies, more than at any other major cancer center, according to a review by the Times and ProPublica. Baselga has since resigned from the hospital and the two boards he served on. And a day after the physicians’ meeting on Oct. 1, Thompson resigned from the boards of the pharmaceutical giant Merck and Charles River Laboratories, a healthcare company, that together had paid him $585,050 in compensation in 2017.